Literature DB >> 16608916

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.

Ruggero Galici1, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn.   

Abstract

Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. However, the relative contributions of the mGluR2 and mGluR3 subtypes to the effects of the group II mGluR agonists remain unclear. In the present study, we describe an alternate synthesis and further pharmacological characterization of a recently reported positive allosteric modulator of mGluR2 termed biphenyl-indanone A (BINA). In recombinant systems, BINA produced a robust and selective potentiation of the response of mGluR2 to glutamate with no effect on the glutamate response of other mGluR subtypes. In hippocampal brain slices, BINA (1 microM) significantly potentiated the mGluR2/3 agonist-induced inhibition of excitatory synaptic transmission at the medial perforant path-dentate gyrus synapse. BINA was also efficacious in several models predictive of antipsychotic- and anxiolytic-like activity in mice. The behavioral effects of BINA were blocked by the mGluR2/3 antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), suggesting that the in vivo effects of BINA are mediated by increased activation of mGluR2. Collectively, these results indicate that BINA is a selective mGluR2 positive allosteric modulator and provide further support for the growing evidence that selective allosteric potentiators of mGluR2 mimic many of the in vivo actions of mGluR2/3 agonists that may predict therapeutic utility of these compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608916     DOI: 10.1124/jpet.106.102046

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  67 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  mGluR2-Positive allosteric modulators: Therapeutic potential for treating cocaine abuse?

Authors:  James E Barrett
Journal:  Neuropsychopharmacology       Date:  2010-09       Impact factor: 7.853

3.  Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222.

Authors:  Maarten L J Doornbos; Laura Pérez-Benito; Gary Tresadern; Thea Mulder-Krieger; Ilse Biesmans; Andrés A Trabanco; Jose María Cid; Hilde Lavreysen; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2016-01-13       Impact factor: 8.739

Review 4.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

5.  Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.

Authors:  Shen Yin; Meredith J Noetzel; Kari A Johnson; Rocio Zamorano; Nidhi Jalan-Sakrikar; Karen J Gregory; P Jeffrey Conn; Colleen M Niswender
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

6.  Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism.

Authors:  Alfred Hetzenauer; Corrado Corti; Stefanie Herdy; Mauro Corsi; Francesco Ferraguti; Nicolas Singewald
Journal:  Psychopharmacology (Berl)       Date:  2008-09-24       Impact factor: 4.530

Review 7.  Promise of mGluR2/3 activators in psychiatry.

Authors:  P Jeffrey Conn; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2009-01       Impact factor: 7.853

Review 8.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 9.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

10.  Allosteric modulators for mGlu receptors.

Authors:  F Gasparini; W Spooren
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.